In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Ionsys fentanyl pump for post-surgical pain to launch in 2007

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson subsidiary Alza will launch in 2007 its Ionsys needle-free, patient-activated iontophoresis transdermal fentanyl drug delivery system for post-operative pain, the firm says. FDA approved the system May 22 for short-term management of post-operative pain in adults requiring opioid analgesia during hospitalization. Ionsys' E-Trans delivery technology uses low-intensity electrical current to move a 40 mcg dose of fentanyl from a reservoir into the skin over a 10-minute period. Alza also markets the controlled-release fentanyl patch Duragesic. The road to approval for Ionsys has been relatively long. A September 2003 NDA filing was deemed "approvable" in July 2004. The company resubmitted the application in November 2005...

You may also be interested in...



Transport Pharma Targets Cold Sores With Drug-Device Combination Product

A combination product that delivers drugs through the skin via low-voltage electric current could represent an affordable approach to treating cold sores, according to Transport Pharmaceuticals

Clarification

"The Gray Sheet" incorrectly characterized Johnson & Johnson's Ionsys transdermal, on-demand analgesic drug dosing system as a pump. The device uses iontophoresis to deliver fentanyl (1"The Gray Sheet" May 29, 2006, In Brief)...

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

UsernamePublicRestriction

Register

MT023599

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel